Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension. 1991

A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
Department of Clinical Pharmacology, Ernst Moritz Arndt University, Greifswald, FRG.

Pharmacokinetic studies with the arterial chemoreceptor stimulant almitrine (100 mg per os) were performed in 12 healthy volunteers and 8 patients with essential hypertension stage I in order to evaluate the suitability of the drug for physiological tests. The parent compound was determined gas-chromatographically. Almitrine was absorbed with maximal serum levels after 1.8 +/- 0.4 h in healthy volunteers and 1.5 +/- 0.3 h in patients. The elimination proceeded biexponentially with terminal half-lives from 14.6 to 43.4 h in volunteers and 12.5-45.0 h in patients. Further characteristics were large distribution volumes (16.1 +/- 4.5 ml/g in healthy volunteers, 13.9 +/- 4.7 ml/g in patients) and large interindividual variations of all pharmacokinetic parameters by a factor of 2 to 6. Significant differences between healthy individuals and patients were not observed. The drug was well tolerated. The pharmacokinetic properties of almitrine should be included into its evaluation as a test compound.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D015765 Almitrine A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. Almitrine Bismesylate,Almitrine Bis(methanesulfonate),Almitrine Dimesylate,Almitrine Monomesylate,Vectarion,Monomesylate, Almitrine

Related Publications

A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
January 2002, Biopharmaceutics & drug disposition,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
November 1998, Biopharmaceutics & drug disposition,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
January 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
January 1995, Diagnostic microbiology and infectious disease,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
January 1987, European journal of clinical pharmacology,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
February 2021, Clinical pharmacokinetics,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
December 1987, British journal of clinical pharmacology,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
October 2014, The Journal of pharmacy and pharmacology,
A Wilke, and W Siegmund, and T Schneider, and M Wiersbitzky, and G Franke
January 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!